logo
Climbing higher: Women in Construction Week celebrates a growing demographic in the industry

Climbing higher: Women in Construction Week celebrates a growing demographic in the industry

Boston Globe09-03-2025
Plumber Maria Zammitti, working at 585 Kendall in Cambridge; her mother was a construction worker in the 1980s.
David L. Ryan/Globe Staff
Lauren Slaven, a senior superintendent at construction management firm Shawmut Design and Construction in Boston, has spent more than two decades in the industry. When Slaven arrived at Wentworth Institute of Technology in 2000, she wanted to be an architect. But through the school's co-op program, she found herself at a construction meeting detailing renovation plans for the Harvard University Faculty Club. The project superintendent commanded the room, understood all aspects of the job, and was pushing it to the finish line.
'I was like: I want
that
guy's job,' Slaven said.
Related
:
Advertisement
Slaven on Thursday won the mentorship award at the Associated General Contractors of Massachusetts annual Inspire Awards, which honor exemplary women in the construction business.
At Shawmut, Slaven started with a three-year rotation program, spending one year learning project management, another learning estimating, and another learning the role of a superintendent. When she started, maybe one-quarter of her rotation's 20-person cohort were women. The most recent cohort was about half women, she said.
Kumba Wahkor (center) rode the hoist/elevator to the sixth floor of 585 Kendall.
David L. Ryan/Globe Staff
Shawmut's culture is one where teammates push for others to improve and rise up, Slaven said, whether it be giving someone credit or being an unofficial mentor.
'Their generosity and inspiration and really what they saw in me that I may not have seen in myself — they really believed in me from the beginning,' Slaven said. 'I thought to myself: I need to be paying this forward. Mentorship is a critical role. Because it's not just about teaching technical skills to somebody else. It's about inspiring somebody's confidence, and encouraging their growth.'
Advertisement
Ironworker Hannah Cahill at 585 Kendall in Cambridge.
David L. Ryan/Globe Staff
At the AGC awards, Lieutenant Governor Kim Driscoll emphasized the importance of a diverse workforce and how the administration values diversity, equity, and inclusion, drawing strong applause from the nearly 1,000 attendees.
'What makes Massachusetts a strong state is the fact that we have a rich mix of people, a rich tapestry of communities,' Driscoll said. 'What makes us special, I think, is that we recognize that when we utilize everyone, when we make room at the table for people who may not have historically been at that table, we get better outcomes, better results.'
Ironworker Shellian Capo-Chichi on site at 585 Kendall.
David L. Ryan/Globe Staff
Catherine Carlock can be reached at
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap
TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap

Yahoo

timean hour ago

  • Yahoo

TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap

TX RX Systems Deepwave Antennas BUFFALO, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- TX RX Systems, a leader in RF conditioning and communications technology for nearly five decades, has announced the launch of its new Deepwave antenna series. This is a comprehensive product line designed to serve as the next-generation solution for organizations seeking high-performance VHF and UHF omnidirectional antennas similar to those found in now-unavailable legacy lines. Engineered and manufactured on-site in the United States, Deepwave antennas deliver industry-proven performance at a significantly lower cost than comparable offerings currently available in the market. Designed for both mission-critical and commercial applications, the line is suitable for integrators, public safety agencies, utilities, transportation providers, manufacturing facilities, government entities, and any organization requiring durable, broadband RF coverage. The new Deepwave series features wideband coverage across VHF and UHF ranges, allowing flexible deployment across multiple systems and jurisdictions. Models are available with nominal gains ranging from 3 dBd to 9 dBd, providing consistent coverage and minimal distortion throughout the entire operating band. Low VSWR, typically 1.5:1 or less across the specified frequency range, ensures efficient power transfer and reduced reflected power. Each antenna is designed to handle high transmit power levels, making them ideal for both high-site and dense urban installations. Durability is a core design priority for the Deepwave line. Heavy-duty fiberglass radomes and stainless steel hardware protect against extreme weather conditions including high winds, ice loading, and salt fog exposure. All models are engineered to meet or exceed ANSI/TIA-222 standards for structural integrity, ensuring reliable operation even in the harshest environments. 'With the discontinuation of several long-standing antenna product lines in the market, organizations are actively seeking drop-in replacements that match or exceed the performance of their existing infrastructure,' said Jay Slomba, Director of Business Operations at TX RX Systems. 'Deepwave antennas are engineered to deliver uncompromising quality at a price point well below what customers are used to paying.' The Deepwave series is available now through the TX RX Systems website. Additional models will be released in the coming months to expand the range and cover even more application requirements. For more information or to request a quote, visit or contact a TX RX Systems Customer & Technical Support Specialist at sales@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033

Yahoo

timean hour ago

  • Yahoo

Human Osteoblasts Market to Reach US$ 87.1 Million by 2033

The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

MotorWeek keeps the throttle pinned into an unprecedented 45th season of television's original automotive magazine
MotorWeek keeps the throttle pinned into an unprecedented 45th season of television's original automotive magazine

Yahoo

time2 hours ago

  • Yahoo

MotorWeek keeps the throttle pinned into an unprecedented 45th season of television's original automotive magazine

MotorWeek TV series gears up for its 45th season premiere MotorWeek's talent team OWINGS MILLS, MD, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Throughout its first 44 seasons, MotorWeek has consistently delivered great advice to help viewers make intelligent car-buying decisions while keeping things in perspective with a strong sense of automotive history. For Season 45, MotorWeek will continue to bring viewers great automotive advice, but with a heavy dose of nostalgia along for the ride, looking back at four and a half decades of covering America's love affair with the automobile. Switch Auto Insurance and Save Today! The Insurance Savings You Expect Great Rates and Award-Winning Service Affordable Auto Insurance, Customized for You This yearlong celebration kicks off Saturday, September 6, on public television stations across the country (check local PBS listings). Season 45's glances in the rearview mirror will include a special anniversary episode on November 8, as well as frequent throwbacks to memorable car reviews and features from the past. MotorWeek is produced and distributed by Maryland Public Television. 'We're driving deep into our video vault so that viewers can relive some of the most entertaining and magical moments of our first four-plus decades,' says MotorWeek Creator and Host John Davis. 'It's going to be quite a party!' This milestone anniversary season will also feature a completely redesigned high-energy graphics package, delivering a modern, cohesive look from opening theme to closing credits. MotorWeek's celebration doesn't mean the series is taking its eyes off the here and now. With tariffs rising and EV incentives shrinking, the future course of the automotive industry has never been more uncertain. MotorWeek will be there to guide viewers through it all, covering all the powertrain bases, including EVs, traditional internal combustion engines, hybrids, and perhaps the most logical solution of all: plug-in hybrids, which offer the benefits of an EV, eliminate range anxiety, and deliver hybrid fuel efficiency. New vehicle Road Tests continue to be the heart and soul of the program. Host John Davis joins the rest of the MotorWeek team as they hit the road, track, and trail to evaluate upward of 150 new cars, trucks, and utilities hitting the market, regardless of whether they're packing an engine, electric motors or, as is increasingly the case, some combination of both. Season 45 highlights include the Ferrari Roma Spider, Lincoln Navigator, Toyota 4Runner, Hyundai Ioniq 9, Ram 2500, BMW M235, Acura ADX, Porsche 911 Carrera 4 GTS, and a whole lineup of new fully-electric Cadillacs. MotorWeek's rotating roster of feature segments will return, too. 'Over the Edge' reporter Greg Carloss pushes the limits of the automotive world; lifestyle reporter Stephanie Hart keeps viewers up to date on developments in driving and automotive safety, along with the latest in automotive technology in 'FYI'; 'Two Wheelin'' reporter Brian Robinson puts the latest motorcycles to the test; Jessica Ray shares her automotive knowledge with a new round of informative 'Did You Know' segments; and 'AutoWorld' continues to explore the ever-evolving world of cleaner fuels to power modern mobility. For those viewers who still like to turn some wrenches in the garage, our 'Your Drive' quartet of car care experts is featured weekly, with advice to help you make sure your daily driver doesn't let you down. Audra Fordin, founder and CEO of Women Auto Know, seeks to empower people of all ages with the automotive knowledge they need to be safe, confident, and knowledgeable drivers, passengers, and automotive consumers. Daniel Maffett, a seasoned resto-mod veteran and designer of numerous SEMA car builds, brings his artistic eye to MotorWeek, showing you the right way to upgrade your ride. Logan McCombs, who's never run into something he couldn't make better with a few tools in his hands, focuses on general maintenance topics and DIY performance upgrades. And 14-year-old gearhead Giuseppe Iatarola adds a dimension to MotorWeek's car care advice like no other. All Season 45 segments, including road tests, lifestyle, entertainment, and safety features, will continue to be available in the palm of your hand through the MotorWeek app. A free download from your favorite app store, it also doubles as a handy guide to all the new and used clean-fuel vehicles available, under the 'Power Your Choice' tab. MotorWeek airs on 90% of PBS stations nationwide. Viewers can find the days and times their local public television station airs MotorWeek by going to the station listings page on The show's most current episodes can be viewed online at and streamed 24/7 on PBS Living, a Prime Video Channel, as well as viewed on smart devices through the free PBS app. Recently archived episodes are also available on the free streaming service Tubi. Winner of dozens of prestigious automotive journalism awards, MotorWeek returns to the RACER Network cable channel; plus, Spanish-language viewers can once again catch MotorWeek on V-me. Program excerpts covering all segments, including road tests, are available at MotorWeek's YouTube Channel, with more than 500,000 subscribers and nearly three million views per month. Viewers can also follow MotorWeek on Facebook and Instagram, as well as download complete shows on iTunes. In short, if you have a screen, you can watch MotorWeek. MotorWeek is nationally sponsored by Auto Value and Bumper to Bumper and # # # Attachments MotorWeek TV series gears up for its 45th season premiere MotorWeek's talent team CONTACT: Tom Williams Maryland Public Television 4105814031 tomwilliams@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store